Drug Profile
Research programme: VEGF receptor inhibitors - Bayer HealthCare Pharmaceuticals
Alternative Names: ZK 261991Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Developer Bayer HealthCare Pharmaceuticals
- Class Antineoplastics
- Mechanism of Action Vascular endothelial growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Germany (PO)
- 29 Mar 2010 Preclinical development is ongoing in Germany
- 11 May 2007 Preclinical trials in Solid tumours in Germany (PO)